Who supplies Kymera Therapeutics, and who buys from it
Kymera Therapeutics has 0 disclosed suppliers and 4 disclosed customers in SEC filings.
Sources for KYMR relationships
SEC EDGAR · verbatim disclosure
Sources for KYMR relationships
EDGAR · verbatim disclosure · 4Show sources· 4
customer
GILDGilead Sciences, Inc.›
SentenceIn June 2025, we announced a strategic collaboration with Gilead Sciences, Inc. ("Gilead") to develop novel oral molecular glue degraders for CDK2.
SentenceKymera (2020): agreement to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases;
SentenceIn consideration for the exclusive licenses granted to Sanofi under the Sanofi Agreement, Sanofi paid to us an upfront payment of $150.0 million.
SentenceVertex provided us with a non-refundable upfront payment of $50.0 million and purchased 3,059,695 shares of our Series B-1 Convertible Preferred Stock at $6.54 a share, pursuant to a separate, but simultaneously executed Share Purchase Agreement.